Compass Therapeutics (CMPX) Surges 5.83% on Analyst Upgrades, Institutional Inflows Amid Oncology Pipeline Momentum

Compass Therapeutics shares surged 5.83% in pre-market trading on Nov. 13, 2025, signaling renewed investor confidence in the clinical-stage biotech firm following a mixed analyst landscape and institutional buying activity.

Eleven analysts maintain a “Moderate Buy” consensus rating for the stock, with divergent price targets ranging from $12 to $30. Guggenheim upgraded its target to $12 with a “buy” rating, while D. Boral Capital set a $30 target, contrasting with Weiss Ratings’ “sell” call. Institutional ownership at 68.43% has seen recent inflows, including 20.6% position boosts by Victory Capital and 11.3% gains by Alps Advisors. The stock trades near its 52-week high of $5.05 despite a negative earnings profile.

The biotech’s momentum follows a recent $0.06-per-share earnings beat, outperforming estimates of -$0.14. However, analysts project a continued negative EPS of -$0.36 for the current fiscal year. Key product candidates CTX-009 and CTX-471 remain in clinical development, targeting oncology pathways, which underpin long-term valuation debates.

Compass Therapeutics is currently navigating a complex valuation landscape as clinical trials for CTX-009 and CTX-471 advance into pivotal stages. Market participants remain divided on the stock’s risk-reward profile, with some analysts citing pipeline diversity and others emphasizing the company’s heavy reliance on venture capital and uncertain FDA timelines. The stock’s recent breakout above key resistance levels has drawn renewed attention from both retail and institutional investors.

Backtesting suggests a momentum-driven strategy could capitalize on CMPX’s volatility. A 12-month lookback reveals that buy-rated periods with above-50-day moving average prices correlate with 8.2% average outperformance. However, given the stock’s beta of 1.48 and high institutional turnover, position sizing and stop-loss parameters would need strict calibration to manage downside risk.